The annual general asset-sale limit rises to $2.5M in book value under USANA (USNA)'s credit amendment.
USANA Health Sciences, Inc. (USNA) amended its $75 million revolving credit facility, increasing the annual general asset-sale limit from $500,000 to $2.5 million in aggregate book value. The amendment also permits USANA Australia Pty, Ltd to sell its real property in Sydney and use the proceeds, while introducing a new Consolidated EBITDA covenant starting October 3, 2026. This filing, classified as a material event, details changes to financial obligations and certain permitted transactions.
USANA Health Sciences stock reports a Q2 loss before October results
USANA Health Sciences reported a Q2 2026 loss with diluted EPS of negative USD 1.16, compared to a positive USD 0.52 a year prior, on sales of USD 223.3 million, a 5.3% year-over-year decline. The company's operating margin was negative 9% for the quarter, though operating cash flow remained positive at USD 23.3 million. Investors are looking to the upcoming Q3 2026 earnings report on October 28, 2026, to see if sales stabilize amidst pressures in its nutrition and direct-to-consumer businesses.
USANA Health Sciences stock costs EUR 13.20 ahead of results
USANA Health Sciences stock was trading at EUR 13.20 on October 5, 2026, unchanged from its prior close, as the company prepares to announce its third-quarter results on October 28, 2026. This comes after a challenging second quarter where revenue fell 5.30 percent and the company reported a diluted earnings per share loss of USD 1.16. Investors are now looking to the upcoming earnings report to gauge the company's operational execution and compare it against estimated third-quarter revenue of USD 219.02 million and consensus EPS of USD 0.11.
How USANA Health Sciences is helping over 10,000 Utahns suffering from Multiple Sclerosis
USANA Health Sciences CEO Kevin Guest and Phil McCarthey are raising awareness and funds for the over 10,000 Utahns affected by Multiple Sclerosis through the annual Dinner of Champions. Guest, who has lived with MS for 18 years, received the 2026 T.K. McCarthey Silver Hope Award and is using his platform to share his story and highlight the importance of community and support for those with the diagnosis. Funds raised from the event support awareness campaigns and programs for MS patients.
USANA Health Sciences, Inc. (USNA) stock price, news, quote and history
This article provides a detailed overview of USANA Health Sciences, Inc. (USNA) stock, including its current price, key statistics, historical data, and company profile. It covers financial performance metrics, analyst insights, and recent news, positioning USANA as a developer and seller of science-based nutritional and personal care products.
USANA Health Sciences, Inc. (USNA) Stock Price, News, Quote & History
This article provides a detailed overview of USANA Health Sciences, Inc. (USNA), including its current stock price, historical performance data, key financial metrics, and company profile. It highlights the company's product offerings in nutritional, personal care, and skincare products, its market segments, and recent financial performance, including revenue and earnings trends. The information is sourced from Yahoo Finance, offering a comprehensive snapshot for investors.
USNA Forecast — Price Target — Prediction for 2027
This article provides a forecast for USANA Health Sciences, Inc. (USNA) stock, indicating a price target of $25.00 from analysts. It covers various financial metrics, historical performance, earnings reports, and other details relevant to potential investors. The article also includes frequently asked questions about the company's stock.
USANA Health Sciences stock holds steady after recent technical signal update
USANA Health Sciences (USNA) stock is trading around a key technical signal level of USD 14.14 as of September 19, 2026, with weak near-term sentiment but strong mid-term prospects. Recent financial results show stable revenue and resilient margins, supported by share repurchases, while analysts continue to view it as a niche player in the health and wellness sector. The stock currently sits well below its long-term resistance of USD 20.35, indicating potential upside if market sentiment improves.
More than 10,000 Utahns are living with MS and USANA's CEO is one of them
Kevin Guest, CEO of USANA Health Sciences, has publicly shared his personal struggle with Multiple Sclerosis (MS) for the first time. He is being honored with the T.K. McCarthey Silver Hope Award from the National Multiple Sclerosis Society for his dedication to supporting those with MS. Guest's experience with MS has influenced his leadership style, emphasizing purpose and hope, and he encourages a positive attitude despite difficulties.
Empowered Funds LLC Invests $1.50 Million in USANA Health Sciences, Inc. $USNA
Empowered Funds LLC has acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA), purchasing 70,253 shares valued at approximately $1.5 million, which represents about 0.38% of the company. This investment comes as institutional investors collectively own 54.25% of USANA's stock, despite negative analyst sentiment and recent underperformance in earnings, where the company missed revenue and EPS estimates. The stock is currently trading near its one-year low, reflecting broader investor concerns and analyst downgrades.
1,554,189 Shares in USANA Health Sciences, Inc. $USNA Bought by BlackRock Inc.
BlackRock Inc. recently acquired 1,554,189 shares of USANA Health Sciences, Inc. (NYSE:USNA) during the second quarter, valued at approximately $33.2 million, giving BlackRock an 8.42% stake in the company. This comes as USANA Health Sciences reported disappointing quarterly results, missing analyst expectations for both earnings and revenue, and with several analysts downgrading the stock to "sell." Despite this, other institutional investors have also adjusted their holdings in USANA Health Sciences.
USANA CEO Kevin Guest Calls on People to Find a Way to Serve Others, Then Act
USANA Health Sciences CEO Kevin Guest challenges individuals to intentionally integrate service into their lives, drawing from "The Holland Principle" in his book, "All The Right Reasons." Guest emphasizes that even small acts of service can make a significant difference, encouraging people to pay attention to needs around them, start small, and make service a habit. He highlights USANA's humanitarian efforts as an example of impactful service.
Nantahala Capital Management LLC Acquires New Position in USANA Health Sciences, Inc. $USNA
Nantahala Capital Management LLC has acquired a new position in USANA Health Sciences, Inc. (NYSE:USNA), purchasing 810,074 shares valued at approximately $17.3 million, giving them a 4.39% stake in the company. This comes as institutional investors collectively own 54.25% of the stock, while analyst sentiment has deteriorated with an average "Sell" rating. USANA Health Sciences recently missed quarterly earnings expectations, reporting a loss of $0.07 per share against a consensus estimate of $0.43, and revenue of $223.27 million against an expected $235 million, with shares opening near their 52-week low at $14.06.
USANA unveils protein, creatine and electrolyte drink mix
USANA Health Sciences has launched Clear Protein + Creatine Mix, a 3-in-1 drink designed for active adults. This new product combines clear whey protein isolate, micronized creatine monohydrate, and electrolytes into a single 50-calorie drink, offering an alternative to traditional protein shakes. It is available in Twisted Citrus and Green Apple flavors and is manufactured in an FDA-registered, GMP-certified facility.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
USANA Health Sciences (USNA) is currently rated a Zacks Rank #2 (Buy) with a Value grade of A, making it an attractive stock for value investors. The article highlights several key valuation metrics, including a PEG ratio of 0.78, a P/B ratio of 1.04, and a P/CF ratio of 8.43, all of which compare favorably to industry averages. These indicators suggest that USNA is likely undervalued, especially when considering its strong earnings outlook.
ETFs Investing in USANA Health Sciences, Inc. Stocks
This article lists various ETFs that include USANA Health Sciences, Inc. (USJ) stock in their portfolios. It provides a detailed table of 26 such funds, including their market value, weight of USJ stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs listed range from broad market funds to more specialized small-cap, value, and sector-specific funds.
1,205,587 Shares in USANA Health Sciences, Inc. $USNA Bought by Pzena Investment Management LLC
Pzena Investment Management LLC has acquired 1.21 million shares of USANA Health Sciences (NYSE:USNA) worth approximately $25.7 million, establishing a 6.53% stake in the company. This comes as USANA Health Sciences faces negative analyst sentiment, including "Sell" ratings, recent downgrades, and insider selling activity totaling $261,441 in the past 90 days. The company's shares opened near their 12-month low after missing analyst expectations for its quarterly earnings and revenue.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences (NYSE: USNA) has launched its Clear Protein + Creatine Mix, a new 3-in-1 active nutrition drink combining clear whey protein isolate, micronized creatine monohydrate, and electrolytes. Each 50-calorie serving provides 10g of protein, 5g of creatine, and over 600mg of electrolytes, designed for adults with active lifestyles seeking a simpler and lighter alternative to traditional protein shakes. The product is available in Twisted Citrus and Green Apple flavors and is manufactured in an FDA-registered, GMP-certified facility.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences has launched its new Clear Protein + Creatine Mix, a 3-in-1 drink designed to simplify daily nutrition for active adults. This single beverage combines 10g of clear whey protein isolate, 5g of micronized creatine monohydrate, and over 600mg of electrolytes in just 50 calories. The product aims to provide a convenient and refreshing alternative to consuming separate protein, creatine, and hydration supplements.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences has launched Clear Protein + Creatine Mix, a new 3-in-1 drink mix combining clear whey protein isolate, micronized creatine monohydrate, and electrolytes. Designed for active adults, each 50-calorie serving provides 10g of protein, 5g of creatine, and over 600mg of electrolytes, simplifying daily nutrition routines. The product is available in Twisted Citrus and Green Apple flavors and is free from added sugar, artificial flavors, or colors.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences (NYSE: USNA) has launched Clear Protein + Creatine Mix, a new 3-in-1 drink mix combining 10g of clear whey protein isolate, 5g of micronized creatine monohydrate, and over 600mg of electrolytes in a single 50-calorie serving. This product aims to simplify the daily routines of active adults by consolidating three common supplements into one refreshing, easy-to-mix beverage without artificial flavors or colors. Available in Twisted Citrus and Green Apple, it is designed for everyday performance and manufactured in an FDA-registered, GMP-certified facility.
Usana Health Sciences | 10-Q: Q2 2026 Earnings Report
This document is the Q2 2026 Earnings Report (10-Q filing) for Usana Health Sciences. It contains the complete financial and operational disclosures for the second quarter of 2026 as required by regulatory bodies.
USANA Health Sciences (USNA) sees Renaissance report 5.19% equity stake
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have disclosed a 5.19% equity stake in USANA Health Sciences Inc. As of June 30, 2026, these entities beneficially own 958,520 shares of USANA common stock, exercising sole voting and dispositive power. The filing, an amended Schedule 13G/A, indicates that certain funds managed by Renaissance Technologies LLC will receive dividends and proceeds from the sale of these securities.
USANA Health Sciences Q2 Earnings Call Highlights
USANA Health Sciences (NYSE: USNA) lowered its full-year outlook due to increased digital customer acquisition costs for its Hiya brand and a packaging issue with Rise Wellness, resulting in significant revenue and margin pressure. Despite these challenges, the core nutrition business performed as expected, showing momentum in mainland China and early recovery in North Asia. The company recorded a $29 million non-cash goodwill impairment related to Hiya but maintained strong financial flexibility with $169 million in cash and no debt.
USANA Health Sciences (NYSE:USNA) Rating Lowered to Strong Sell at Zacks Research
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) to a "strong sell" from "hold," contributing to a consensus "sell" rating for the stock. This follows USANA's recent quarterly report, where the company missed EPS and revenue estimates and issued a lower-than-expected FY2026 EPS guidance. Shares opened near their 52-week low, and insiders have sold a significant amount of stock recently.
USANA Health Sciences (NYSE:USNA) Cut to "Hold" at Wall Street Zen
USANA Health Sciences (NYSE:USNA) has been downgraded to a "Hold" rating by Wall Street Zen, adding to previous downgrades from other analysts, resulting in an overall consensus rating of "Reduce." This follows the company missing earnings expectations in its latest quarter, reporting an adjusted loss of $0.07 per share against an estimated $0.43, and revenue of $223.27 million against an expected $235 million. Shares opened near their 12-month low, and insiders have sold over $261,000 worth of stock recently.
USANA Health Sciences (USNA) Stock Sinks After Hiya Impairment And Loss Shock
USANA Health Sciences (USNA) experienced a significant stock drop of 34.2% after reporting a Q2 2026 loss per share of US$1.16 on revenue of US$223.3m, compounded by a US$29m non-cash goodwill impairment related to its Hiya brand. The company swung from a profit of US$9.7m in Q2 2025 to a loss of US$21.4m in Q2 2026, raising concerns about its profit quality and multi-brand expansion strategy despite a seemingly strong core nutritional business and balance sheet.
USANA Health Sciences (USNA) Stock Sinks After Hiya Impairment And Loss Shock
USANA Health Sciences (USNA) experienced a significant stock drop of 34.2% after reporting a Q2 loss of US$1.16 per share and a US$29m goodwill impairment related to its Hiya brand. The company's revenue declined by 5.3% year-over-year, and it swung from a profit to a substantial loss, raising concerns about its profit quality and multi-brand expansion strategy despite a strong balance sheet and core nutritional business.
USANA Health Sciences, Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
NULL
Should USANA Health Sciences (USNA) Revisit Its Valuation After Lowered Guidance And Q2 Loss?
USANA Health Sciences (USNA) experienced a significant share price drop and reported a Q2 2026 net loss, lowered full-year guidance, and a $29 million goodwill impairment. Despite these setbacks, Simply Wall St's analysis suggests the stock is undervalued with a Price-to-Sales ratio of 0.3x compared to peers and an estimated fair value of $43.64 per share based on its DCF model. Investors are advised to review the underlying data and potential risks, although the current valuation implies a substantial discount.
Earnings call transcript: USANA Health Sciences posts Q2 2026 loss, stock sinks 28%
USANA Health Sciences (USNA) reported a significant Q2 2026 loss of 7 cents per share on $223 million revenue, widely missing analyst expectations, leading to a 28% stock decline. The loss was attributed to a non-cash goodwill impairment for its Hiya unit, a packaging issue with Rise Wellness, and a challenging digital advertising environment. Despite these setbacks, the company emphasized the stability of its core nutritional business, renewed momentum in Greater China, and a strong balance sheet with $169 million in cash and no debt.
Why USANA (USNA) Stock Is Nosediving
Shares of USANA Health Sciences (USNA) dropped significantly after the company reported second-quarter 2026 results that missed Wall Street's revenue and earnings expectations, posting an adjusted loss per share against forecasts for a profit. This steep decline overshadowed the reaffirmation of its full-year revenue guidance and a recent partnership renewal with Nordiq Canada. The company's stock has been volatile and is down 18.2% since the beginning of the year.
USANA Reports Q2 2026 Financial Results
USANA Health Sciences, Inc. announced its Q2 2026 financial results, with net sales of $223 million and a net loss of $21.4 million. The company experienced mixed performance, with its Core Nutritional business meeting expectations but its ventures, Hiya and Rise Wellness, performing below expectations due to digital marketing challenges and packaging disruptions. Despite these setbacks, USANA remains confident in its strategic transformation to a diversified omnichannel health and wellness company and plans to evolve its Brand Partner incentive plan, accelerate product innovation, and modernize technology for long-term growth.
USANA Chairman, CEO Kevin Guest Shares 5 Ways to Make Happiness Happen at Work and Home This August
Kevin Guest, Chairman and CEO of USANA Health Sciences, offers five practical tips to cultivate happiness during August's Happiness Happens Month. These tips include noticing existing good, creating moments of joy, recognizing others, helping without being asked, and protecting time for important people and priorities. Guest emphasizes that happiness is a choice and a practice that enhances both work and personal life.
USANA CEO's Parents Bought a Piano Before a Car—They Still Own It
USANA Health Sciences CEO Kevin Guest shares five happiness tips for both work and home to celebrate Happiness Happens Month in August. He emphasizes intentionally noticing good things, creating joyful moments, recognizing others, helping without being asked, and protecting time for important relationships. Guest relates these tips to his "Piano Principle," encouraging people to actively make space for what truly matters in their lives.
Lazard Asset Management LLC Invests $1.26 Million in USANA Health Sciences, Inc. $USNA
Lazard Asset Management LLC has acquired a new stake of 72,395 shares in USANA Health Sciences, Inc. (NYSE:USNA) worth approximately $1.26 million. This investment gives Lazard Asset Management a 0.39% stake in the company, where institutional investors and hedge funds collectively own 54.25%. USANA Health Sciences recently reported a quarterly loss and missed revenue expectations, and analyst sentiment remains negative with a consensus "Reduce" rating.
USANA Updates 2026 Sales Outlook After Hiya, Rise Fall Short
USANA Health Sciences reported a Q2 2026 net loss of $(21.4) million, including a $29.1 million impairment charge, and updated its fiscal year 2026 sales outlook downward due to underperformance in its Hiya and Rise Wellness ventures. The company's core nutritional business performed as expected, but Hiya faced digital marketing challenges and Rise Wellness experienced a packaging disruption. Despite these setbacks, USANA remains confident in its long-term strategy to diversify into an omnichannel health and wellness company.
USANA Health Sciences (USNA) Reports Q2 Loss, Lags Revenue Estimates
USANA Health Sciences (USNA) reported a Q2 loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.43, and revenues of $223.27 million, falling short of the $235.85 million reported a year ago. Despite outperforming the market year-to-date with a 16.4% stock gain, the company's current Zacks Rank is #3 (Hold), indicating that its shares are expected to perform in line with the market. Investors are now awaiting management's commentary on the earnings call to gauge future stock movement.
USANA Health Sciences Reports Second Quarter 2026 Results
USANA Health Sciences reported mixed Q2 2026 results, with consolidated net sales of $223 million and a net loss of $(21.4) million, including a $29.1 million impairment charge. The Core Nutritional business met expectations, but Hiya and Rise Wellness performed below forecasts, leading to updated fiscal year 2026 guidance with lower revenue and earnings projections. Despite these challenges, USANA remains committed to its strategy of transforming into a diversified, omnichannel health and wellness company.
USANA Health Sciences (NYSE:USNA) Posts Earnings Results, Misses Estimates By $0.50 EPS
USANA Health Sciences (NYSE:USNA) reported quarterly earnings, missing analyst estimates with a loss of $0.07 per share against a projected $0.43 profit, and revenue of $223.27 million, below the $235 million estimate. Shares traded up $0.05 to $22.89, giving the company a market capitalization of $422.53 million. Insider selling of 17,660 shares occurred, while institutional investors hold 54.25% of the stock, and analysts maintain a "Reduce" consensus rating despite one upgrade to "buy."
USANA Health Sciences (NYSE: USNA) swings to Q2 loss, trims 2026 forecast
USANA Health Sciences reported a Q2 2026 net loss of $(21.4) million, a significant swing from a net gain of $9.7 million in the prior year, primarily due to a $29.1 million goodwill impairment charge related to its Hiya reporting unit. The company also reduced its fiscal 2026 outlook, forecasting lower consolidated net sales and a net loss, citing challenges in Hiya's digital marketing and a packaging disruption for Rise Wellness. Despite these setbacks, USANA maintains a strong balance sheet with $169 million in cash and no debt, and remains confident in its long-term strategy to evolve into a diversified health and wellness company.
Earnings To Watch: USANA (USNA) Reports Q2 Results Tomorrow
USANA Health Sciences (USNA) is set to report its Q2 earnings this Tuesday. The market expects flat year-on-year revenue, a slowdown from last year's 10.8% increase, despite analysts reconfirming estimates. The company has a history of missing Wall Street's revenue estimates multiple times over the last two years, contrasting with some consumer staples peers who recently reported strong revenue growth.
USANA Health Sciences, Inc. Revenue Breakdown – NYSE:USNA
USANA Health Sciences, Inc. (NYSE: USNA) reported total revenue of $925.26 million USD last year. The Core Nutritional segment was the top performer, generating $775.45 million USD, while China was the largest regional contributor with $381.82 million USD in revenue.
Glow-Promoting Cellular Nutrition Formulas
USANA Health Sciences has shared the results of a 12-week consumer trial for its skincare supplement, Glow, which is designed to promote healthy and radiant skin from within. The study showed that over 97% of participants experienced improvements in skin brightness, radiance, and evenness, with more than 80% also noting better hydration, firmness, and elasticity. Glow's formula includes Damasty (rose extract, bioactive melon superoxide dismutase, acerola cherry vitamin C), astaxanthin, and grape seed oil, tapping into the growing trend of ingestible skincare and evidence-backed beauty products.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study for its skincare supplement, Glow, showing significant improvements in participants' skin. The study, involving 36 individuals in the U.S. and Mexico, reported high percentages of brighter-looking, more radiant, and even-toned skin, along with improved hydration, firmness, and elasticity. These findings underscore USANA's philosophy of internal nutrition for external beauty, backed by the science of its Damasty®-infused formula.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study on its skincare supplement, Glow, showing significant improvements in skin appearance. Participants reported brighter, more radiant, and even-toned skin, along with improved hydration, firmness, and elasticity. The study, conducted across the United States and Mexico, highlights the product's effectiveness in supporting healthy skin from within.
Glow-Promoting Cellular Nutrition Formulas
USANA Health Sciences has introduced Glow, a cellular nutrition supplement designed to promote healthy, radiant skin. A 12-week consumer trial involving 36 participants showed that over 97% experienced improvements in brightness and skin tone, with significant gains in hydration, firmness, and elasticity. The product's formulation includes Damasty, astaxanthin, and grape seed oil, tapping into growing trends in ingestible and clinically validated skincare.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study on its skincare supplement, Glow, revealing significant improvements in skin appearance. Participants reported enhanced brightness, radiance, and more even skin tone, with high percentages also noting better hydration, firmness, and elasticity. The study highlights USANA's commitment to science-backed products that deliver visible benefits for healthy skin from within.
USANA Health Sciences Number of Employees 2026 | Employee Count & Headcount Data
USANA Health Sciences (USNA) had 1,580 employees worldwide as of March 2026, marking a 4.6% decline from 2023. The company's workforce is primarily concentrated in the United States, Philippines, and Canada, with Mexico being its fastest-growing location. USANA is actively hiring, though job postings have significantly decreased, and employee sentiment is neutral but declining.
USANA Health Sciences Inc (USNA) Financial Health: Profitability & Balance Sheet Analysis
USANA Health Sciences Inc (USNA) currently boasts a robust financial score of 8.24, ranking 12th in the Food & Tobacco industry. The company reported a quarterly revenue of $250.22 million, showing a 0.27% year-over-year increase, and a significant 20.07% year-over-year increase in net profit. However, several specific financial data points like cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company.
